Join CooperVision at Academy 2025 - Where Innovation Meets Impact. Booth #1533
Join us at Academy 2025 where innovation meets impact. CooperVision is proud to showcase our industry-leading myopia management portfolio, featuring MiSight® 1 day* —the dependable,*†1 proven*‡2 and lasting soft contact lens for myopia control.*§◊3,4
Learn how to make a lasting difference in a child’s life and take this opportunity to be part of the future of vision care today.
- Discover the impact you can make to improve children’s lives with a contact lens treatment that provides BOTH clear vision and myopia control to help protect their vision for the future.*¶††2,5
- See how easy it is to prescribe MiSight® 1 day — a simple, effective solution that fits seamlessly into your practice.
- Learn from experts about the science, results, and efficacy of MiSight® 1 day — and how to take that information and talk to parents about myopia control.
MiSight® 1 day - Setting the Standard in Myopia Control
Save the Date for Can't Miss Events
No registration required.
Industry Innovation Lunch & Learn
Advance the Myopia Control Herd
Myopia control only works when children not only use the treatment but thoroughly enjoy it—that's what's been shown with over 200,000 patients in MiSight® 1 day.*6 Easily take on myopia with a refreshed mindset and bite size steps that make a difference, refusing to let myopia win. Together, the future can be brighter as we collectively deliver this standard of care.
| Wednesday, October 8, 2025 |
| Room 208 |
Speakers
Academy Breakfast Talk
Kids Can Do Hard Things (And So Can We!)
What if every child believed anything’s possible? Michael Bonner, award-winning educator, author, and children’s advocate, will share a powerful message of resilience, empathy, and action. In a world where it’s easy to choose what’s familiar, like single vision correction for myopia, Bonner will inspire you to lead with intention and create change, even when it seems hard. Because with belief, trust, and support, kids and the people who care for them can rise to any challenge.
|
| Thursday, October 9, 2025 |
|
| Room 206AB |
Speaker
Vision Equity Panel Discussion
Explore how the eye care community can close gaps in access to vision care, particularly for children and underserved populations. The discussion will examine inequities in vision health and spotlight collaborative strategies—awareness, access, and affordability—that practitioners, policymakers, nonprofits, and industry can drive together.
Speakers
- Michael Bonner, Educator and Motivational Speaker
- Dr. Michele Andrews, CooperVision
- Dr. Amie Hsieh, The Health Foundation of Central Massachusetts
- Gary Chu, OD, MPH, FAAO, VP Professional Affairs New England College of Optometry
|
| Thursday, October 9, 2025 |
|
| CooperVision Booth #1533 |
Academy 2025 Boston Event Hours
Organized by American Academy of Optometry
|
| October 08 - October 11, 2025 |
|
| Thomas M. Menino Convention & Exhibition Center (MCEC) |
Get In Touch
Have a CooperVision Myopia Management Specialist contact me.
I would like to contact customer service.
- INDICATIONS AND BRIEF SAFETY INFORMATION for MiSight® 1 day soft contact lens:
INDICATIONS:
MiSight® 1 Day (omafilcon A) Soft (Hydrophilic) Contact Lenses for Daily Wear is a prescription device indicated for the correction of nearsightedness and for slowing the progression of nearsightedness in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatismBRIEF SAFETY INFORMATION:
Rx only; results may vary.
ATTENTION: Reference MiSight.com/safety for a complete listing of Indications and Important Safety Information.
INDICATIONS: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.
WARNINGS: Problems with contact lenses could result in serious injury to the eye. Do not expose contact lenses to water while wearing them. Under certain circumstances MiSight® lenses optical design can cause reduced image contrast/ghosting/halo/glare in some patients that may cause difficulty with certain visually-demanding tasks.
PRECAUTIONS: Daily wear single use only. Patient should always dispose when lenses are removed. No overnight wear. Patients should exercise extra care if performing potentially hazardous activities.
ADVERSE EVENTS: Including but not limited to infection/inflammation/ulceration/abrasion of the cornea, other parts of the eye or eyelids. Some of these adverse reactions can cause permanent or temporary loss of vision. If you notice any of the stated in your child, immediately have your child remove the lenses and contact your eye care professional.
†When treatment was initiated between ages 8-12, it reduced the probability of fast eye growth, defined as >0.3 mm of axial elongation over 3 years, by 95%.
‡Compared to a single vision 1 day lens over a 3-year period.
§Year 7 results from the international MiSight® 1 day clinical study found that the mean axial elongation showed no evidence of rebound. ◊Preliminary international study data shows that, on average, for children that discontinued treatment at age 14-19 following 3 or 6 years of MiSight® 1 day wear, the eye growth reverted to age-expected average myopic progression rates.
Disclaimer: The stability of the myopia reduction effect 1-year post-treatment is being further evaluated in a post-approval study in the U.S. as a condition of FDA approval for MiSight 1 day.
¶ActivControl® technology in MiSight® 1 day contact lenses slows axial length elongation and corrects refractive error for age-appropriate children.
††MiSight® 1 day shows sustained slowing of eye growth over time on average. While eyes are still growing; children fit ages 8-12 and followed for 6-years. n=40.
1. Chamberlain P, Hammond DS, Arumugam B, Bradley A. Six-year cumulative treatment effect and treatment efficacy of a dual focus myopia control contact lens. Ophthalmic Physiol Opt. 2024 Jan;44(1):199-205.
2. Chamberlain P, et al. A 3-year randomized clinical trial of MiSight® lenses for myopia control. Optom Vis Sci. 2019; 96(8):556-567.
3. Chamberlain P, Arumugam B, et al. Myopia progression on cessation of Dual-Focus contact lens wear: MiSight 1 day 7 year findings. Optom Vis Sci 2021;98:E-abstract 210049.
4. Hammond D, Arumugam B, et al. Myopia Control Treatment Gains are Retained after Termination of Dual-focus Contact Lens Wear with no Evidence of a Rebound Effect. Optom Vis Sci 2021;98:E-abstract 215130.
5. Chamberlain P et al. Long-Term Effect of Dual-Focus Contact Lenses on Myopia Progression in Children: A 6-year Multicenter Clinical Trial. Optom Vis Sci 2022 In Press.
6. CVI data on file 2025. Internal global wearer modeling estimates for the 12-month period of June 2024 to May 2025.
18533 09/25